Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
IFN-ε protects primary macrophages against HIV infection
Carley Tasker, Selvakumar Subbian, Pan Gao, Jennifer Couret, Carly Levine, Saleena Ghanny, Patricia Soteropoulos, Xilin Zhao, Nathaniel Landau, Wuyuan Lu, Theresa L. Chang
Carley Tasker, Selvakumar Subbian, Pan Gao, Jennifer Couret, Carly Levine, Saleena Ghanny, Patricia Soteropoulos, Xilin Zhao, Nathaniel Landau, Wuyuan Lu, Theresa L. Chang
View: Text | PDF
Research Article AIDS/HIV Immunology

IFN-ε protects primary macrophages against HIV infection

  • Text
  • PDF
Abstract

IFN-ε is a unique type I IFN that is not induced by pattern recognition response elements. IFN-ε is constitutively expressed in mucosal tissues, including the female genital mucosa. Although the direct antiviral activity of IFN-ε was thought to be weak compared with IFN-α, IFN-ε controls Chlamydia muridarum and herpes simplex virus 2 in mice, possibly through modulation of immune response. We show here that IFN-ε induces an antiviral state in human macrophages that blocks HIV-1 replication. IFN-ε had little or no protective effect in activated CD4+ T cells or transformed cell lines unless activated CD4+ T cells were infected with replication-competent HIV-1 at a low MOI. The block to HIV infection of macrophages was maximal after 24 hours of treatment and was reversible. IFN-ε acted on early stages of the HIV life cycle, including viral entry, reverse transcription, and nuclear import. The protection did not appear to operate through known type I IFN-induced HIV host restriction factors, such as APOBEC3A and SAMHD1. IFN-ε–stimulated immune mediators and pathways had the signature of type I IFNs but were distinct from IFN-α in macrophages. IFN-ε induced significant phagocytosis and ROS, which contributed to the block to HIV replication. These findings indicate that IFN-ε induces an antiviral state in macrophages that is mediated by different factors than those induced by IFN-α. Understanding the mechanism of IFN-ε–mediated HIV inhibition through immune modulation has implications for prevention.

Authors

Carley Tasker, Selvakumar Subbian, Pan Gao, Jennifer Couret, Carly Levine, Saleena Ghanny, Patricia Soteropoulos, Xilin Zhao, Nathaniel Landau, Wuyuan Lu, Theresa L. Chang

×

Figure 2

Pretreatment with IFN-ε protects macrophages against HIV-1.

Options: View larger image (or click on image) Download as PowerPoint
Pretreatment with IFN-ε protects macrophages against HIV-1.
(A) Effect o...
(A) Effect of pretreatment with IFN-ε on HIV infection. MDMs were treated with IFN-ε for 2, 6, or 24 hours and then infected with HIV. (B) Effect before and after treatment with IFN-ε on HIV infection. MDMs were pretreated with IFN-ε for 24 hours and then infected with HIV. IFN-ε (at the pretreatment concentration) was added back during HIV infection. (C) Effect of IFN-ε on HIV-infected cells. MDMs were infected with HIV for 2 hours and then treated with IFN-ε immediately or 24 hours after viral infection. (D) IFN-ε–mediated HIV protection is reversible. MDMs were treated with IFN-ε for 24 hours, washed, and then cultured in complete medium without IFN-ε for 0, 24, 48, or 72 hours before HIV infection. HIV-luc (JR-FL) was used in all experiments. The absolute value of RLUs in the 0 ng/ml samples ranged from 105 to 107. Results from different donors are shown in A–C. The experiment in D was repeated in MDMs from another donor. Data are mean ± SD of triplicate samples. *P < 0.05, IFN-ε–treated cells vs. untreated controls by independent-samples t test.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts